SOURCE: ClearTrial, LLC

July 26, 2005 09:00 ET

Nuvelo Selects ClearTrial™ for Clinical Trial Optimization, Planning and Budgeting

OAKBROOK TERRACE, IL -- (MARKET WIRE) -- July 26, 2005 -- ClearTrial, LLC a leading provider of Clinical Trial Operations (CTO) software, today announced that Nuvelo, Inc. has selected the ClearTrial™ Planner software to increase efficiencies, accuracy and speed in its planning, budgeting and outsourcing activities. Nuvelo will use the ClearTrial software to expedite study planning and optimize the operational design of its upcoming clinical studies. Nuvelo also licensed additional modules of the ClearTrial software that can assist in its strategic sourcing process and accruals process.

"For Nuvelo it was important that the ClearTrial software could handle the unique aspects of our studies, without getting so complex that it becomes a burden for our people to use," said Gary Titus, Vice President of Finance and Chief Accounting Officer at Nuvelo.

"ClearTrial is thrilled that our software will support Nuvelo and its clinical programs," said Michael Soenen, Chief Operating Officer at ClearTrial. "We expect to have an immediate impact on the speed and successful execution of Nuvelo's studies."

About ClearTrial

ClearTrial, LLC is a leading provider of Clinical Trial Operations (CTO) software. ClearTrial's software helps pharmaceutical, biotechnology, medical device companies and CROs expedite the clinical development process without sacrificing quality of results, by optimizing the operational design of a study to meet the business constraints. The company's flagship product, the ClearTrial Planner™, provides clinical operations, resource planning, and outsourcing departments with a single solution that promotes speed and consistency, while maintaining flexibility to handle different study requirements. For more information please visit www.cleartrial.com.

About Nuvelo

Nuvelo, Inc. is engaged in the discovery, development and commercialization of life improving therapeutics for the treatment of human disease. Nuvelo's clinical pipeline includes three product candidates, alfimeprase, a direct acting thrombolytic for the treatment of acute peripheral arterial occlusion (PAO) and catheter occlusion; rNAPc2, an anticoagulant that inhibits the interaction of factor VIIa and tissue factor and ARC183, a direct thrombin inhibitor that is being developed for use in acute anticoagulant applications. Nuvelo recently identified NU206 as a preclinical development candidate from its proprietary research programs and expects to leverage expertise in secreted proteins and antibody discovery to expand its pipeline and create partnering and licensing opportunities. Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 408-215-4000.

ClearTrial™, ClearTrial Planner™, the ClearTrial logo are trademarks and/or service marks owned by ClearTrial, LLC, which may be registered in certain jurisdictions.

Contact Information

  • Press Contact:
    Karen Rancic
    ClearTrial
    312.933.3409